Sara Zelinskas
Immunology and Microbiology · The Ohio State University
Publications
72
Citations
43
Est. group size
~9
Recurring co-author estimate
Active years
16
Publishing since 2011
Sara Zelinskas works on cancer immunology, focusing on how combining drugs like trabectedin with immune-signaling proteins such as IL-12 can improve treatment of triple-negative breast cancer, an aggressive cancer subtype with few targeted therapy options. Her recent work also examines side effects of combined chemotherapy and immunotherapy in breast cancer patients treated at multiple medical centers. This research aims to make cancer treatments more effective by better harnessing the immune system to attack tumors.
Publication output was minimal before 2022 but increased sharply from 2023 onward, with a large concentration of outputs (including many supplementary materials tied to a single major study) in 2024 and 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Supplementary Figure S6 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2026
- Supplementary Table S1 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2026
- Supplementary Figure S3 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2026
- Supplementary Figure S1 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2026
- Supplementary Figure S2 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2026
- Supplementary Table S3 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2026
- Supplementary Figure S7 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2026
- Supplementary Table S2 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2026
- Supplementary Figure S5 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2026
- Supplementary Figure S4 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2026
- Supplementary Table S4 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2026
- Supplementary Figure S8 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2026
- Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
Cancer Immunology Research · 2025
- Adverse events in patients treated with neoadjuvant chemo/immunotherapy for triple negative breast cancer: results from seven academic medical centers
Breast Cancer Research and Treatment · 2025
- Figure 2 from Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer
2025
- Cancer Immunology Research×1
- Breast Cancer Research and Treatment×1
- Molecular Cancer Research×1
- Journal of Clinical Investigation×1
- Cancer Control×1
- Gabriella Lapurga
Immunology and Microbiology · The Ohio State University
- Emily Schwarz
Immunology and Microbiology · The Ohio State University
- Jianying Li
Immunology and Microbiology · The Ohio State University
- Carter Allen
Immunology and Microbiology · The Ohio State University
- Andrew Stiff
Immunology and Microbiology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile